Abbott Laboratories (ABT) — Fair Value Analysis

Base-case fair value (P50): $74.57 · Current price: $84.47 · Verdict: Fairly Valued

The Verdict on ABT

Based on rigorous Monte Carlo simulations, Abbott Laboratories (ABT) is currently assessed as Fairly Valued. The current price for ABT stands at $84.30. Our independent analysis yields a median fair value (P50) of $74.45, which implies a -11.7% gap when compared to the present market valuation. Despite the P50 suggesting a premium in the current trading price, the comprehensive probabilistic assessment of ABT’s future cash flows, generated through thousands of simulated forward scenarios, places its current price squarely within the range considered "Fairly Valued." This holistic view considers the full distribution of potential outcomes rather than solely the median, offering a robust perspective on ABT's valuation.

How ABT stacks up against Healthcare

Operating within the dynamic Healthcare sector, Abbott Laboratories' operational and financial health is currently rated as an average quality tier. This assessment reflects ABT's performance metrics and fundamental stability when benchmarked against its industry peers. While the company maintains a significant presence and diversified portfolio within Healthcare, this average tier rating suggests that its financial fortitude and operational efficiency are neither exceptionally strong nor notably weak compared to the sector at large. The current price of $84.30 for ABT therefore reflects a market valuation for a company with an average quality profile in a competitive industry.

What this means for investors

For investors evaluating ABT, the "Fairly Valued" verdict, coupled with a median fair value (P50) of $74.45 against the current price of $84.30—a -11.7% difference—indicates that the stock is priced appropriately within its probabilistic valuation range. While the median suggests the current price is above the central estimate, the overall fair value assessment accounts for a spectrum of potential performance. Understanding the full range of outcomes, including downside and bull cases, is critical. Sign up for a free FairCurve account to access the complete bear and bull case distribution, along with precise probability metrics, and track ABT's fair value as new fundamental data and earnings releases impact its valuation.